Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
{{output}}
Background: Tislelizumab is an anti-programmed cell death protein 1(anti-PD-1) monoclonal antibody, which was approved by the Food and Drug Administration(FDA) on March 14, 2024. However, clinical studies are often limited by sma... ...
